AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04256356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder
Description: Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
Study NCT04256356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding infants with standard formula milk
Description: Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
Study NCT04256356 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding infants
Description: reference group
Study NCT00641914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Study NCT00641914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03406585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProTrans: Allogeneic transplantation with WJMSCs
Description: The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue.
Study NCT03406585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo treatment
Study NCT01334671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
Study NCT00965978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5920 / YM529
Description: oral
Study NCT02890485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling consists of small, monofilament needles that are administered directly into the tissue and manipulated to make the muscle relax for pain relief. This technique is used to treat dysfunctions in skeletal muscle and connective tissue to help diminish pain, reduce impairments of body structure and restore function. Dry needling will be performed in the gluteal or the quadriceps muscle groups depending upon group randomization.
Study NCT02890485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: The same overall procedures will be used as in the true dry needling groups and applied to the same muscle groups (gluteal or quadriceps) depending upon ground randomization. Sham dry needling will be performed using a commercially available sham needling system commonly.This set-up utilizes a blunt tipped needle. When the sham needle is pressed downward, the barrel of the needle retracts into the handle, giving the appearance of insertion of the needle through the skin. This also creates pressure on the subject's skin, increasing the sensation of dry needling. Patients will not be allowed to observe the areas being needled or sham needled.
Study NCT02890485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical Therapy and exercise as determined by the examining clinician based on the patients specific impairments and functional limitations. All subjects enrolled in this study will receive an initial physical therapy (PT) evaluation and then 2 additional PT sessions a week a part. Interventions and prescribed home exercises will be specific to the patients' primary individual impairments as determined during the initial PT evaluation. These interventions reflect current evidence, but will not be restrictive to specific exercises; prescribed exercises will be deemed appropriate based on the treating PTs' examination, evaluation, and identification of each patients' primary deficits, impairments, functional limitations, and current literature.
Study NCT02780726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral
Study NCT03830203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1806
Description: 8 mg/kg
Study NCT03830203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actemra(EU-licensed)
Description: 8 mg/kg
Study NCT03707639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
Study NCT02358096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8232
Description: oral capsule
Study NCT02358096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study NCT03707639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study NCT03767270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRT5201
Description: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles
Study NCT03767270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose in water
Study NCT02189902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU/d D3 over 12 weeks
Study NCT02189902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7000 IU/d D3 over 12 weeks
Study NCT00925405 — intervention group
Intervention type: PROCEDURE
Intervention: Breast MRI
Description: Magnetic resonance imaging (MRI) scans of the breasts once per year
Study NCT00925405 — intervention group
Intervention type: PROCEDURE
Intervention: Mammogram
Description: Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
Study NCT02162680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine
Study NCT02162680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bacteriostatic normal saline (BNS)
Study NCT03468166 — intervention group
Intervention type: OTHER
Intervention: Chronic stroke
Description: The data for motor function and gait pattern analysis was obtained.
Study NCT04060277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Given as SOC
Study NCT04060277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letermovir
Description: Given as SOC
Study NCT03823222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Duckweed protein
Description: 20 grams isolated protein
Study NCT03823222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: 20 grams isolated protein
Study NCT01423214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted surgery
Description: da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
Study NCT01423214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Conventional laparoscopic procedures
Study NCT04060277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM
Study NCT04060277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IM
Study NCT02739347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Trans-cranial direct-current stimulation
Description: Active stimulation group will receive 20 min of 2 mA direct current stimulation.
Study NCT02739347 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Trans-cranial direct current stimulation
Description: This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
Study NCT04538365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan 0.5 % Topical Solution
Description: Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Study NCT04538365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propanolol
Description: Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Study NCT02809144 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve block
Description: Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
Study NCT00705302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group training with self-help group
Description: Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
Study NCT00705302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group training
Description: Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
Study NCT03124199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 400 mg/8 h added to the standard triple therapy
Study NCT00704301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
Study NCT00704301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 times a day
Study NCT01146132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Luxembourg variant of Mediterranean diet + physical activity +/- wine
Description: Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet
Study NCT03422146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea Tree Oil (TTO)
Description: Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
Study NCT03844243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Intramuscular injection
Study NCT03422146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: I-Lid'n Lash® Hygiene
Description: Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks
Study NCT03863678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopemental therapy (NDT)
Description: NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).
Study NCT03863678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopemental therapy (NDT) and dry needling
Description: NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.
Study NCT04509973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: ATC code: H02AB02
Study NCT04509973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: ATC code: H02AB02
Study NCT00993057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Adjustable insulin infusion scale with loading doses
Study NCT03616613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABDOMINAL DUPLEX ULTRASONOGRAPHY
Description: Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
Study NCT00133770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
Study NCT02254148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
Study NCT02254148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: single dose of caffeine given as tablets (day 1 of visits 2 and 3)
Study NCT02254148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: single dose of digoxin given as tablets (day 3 of visits 2 and 3)
Study NCT02254148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: single dose of warfarin given as tablets (day 1 of visits 2 and 3)
Study NCT02254148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
Study NCT02254148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
Study NCT02254148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
Study NCT01817348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine group
Description: * Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~* Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine.
Study NCT03844243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic-saline
Description: Intramuscular injection
Study NCT01794182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide for Injection
Description: Administered as specified in the treatment arm.
Study NCT01794182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT02229279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teleconsulting
Study NCT04335409 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
Study NCT04335409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
Study NCT01817348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT)
Description: - Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
Study NCT01817348 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy (PT)
Description: - Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
Study NCT03734302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole , mutiple dose /oral/empty stomach
Study NCT01928602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TherAppy Language App
Description: Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, \& adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
Study NCT01928602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Games
Description: A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
Study NCT03659916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250 (odevixibat)
Description: A4250 is a small molecule and selective inhibitor of IBAT
Study NCT03118492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT
Study NCT03118492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03118492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03118492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human G-CSF AVI-014
Description: Given IV
Study NCT03118492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03118492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT03118492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT03118492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT03118492 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT01773564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current hospital dressing
Description: Patients were assigned to either arm following a randomization scheme 1:1.
Study NCT01773564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ IV Advanced Securement dressing
Description: Patients were assigned to either arm following a randomization scheme 1:1.
Study NCT01580761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: 14 days of sleep restriction, 4 hours of sleep per day.
Study NCT00352495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00352495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Study NCT00885690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertindole
Description: Sertindole 16-24 mg once daily
Study NCT00885690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 10-20 mg
Study NCT03586336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReDS-Guided
Description: ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
Study NCT03586336 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
Study NCT04319666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left main stenting with intravascular lithotripsy
Description: Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
Study NCT01782872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block (ISB) - 0.375% Ropivacaine + additives
Description: Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous (IV): saline
Study NCT01782872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block (ISB) - 0.2% Ropivacaine + additives
Description: Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline